EpiCypher is an epigenetics company founded in 2012 by Drs. Mark Bedford, Or Gozani, Brian Strahl, and James Bone in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable
epigenetics-focused drug development.
EpiCypher is the global leader in recombinant nucleosome manufacturing and development. Using proprietary methods, we are continuously adding to the world’s largest collection of highly pure modified recombinant “designer” nucleosomes (dNucs™). EpiCypher’s broad dNuc™ diversity is providing a powerful tool to decipher the histone code and accelerate drug development. Shah et al., Wang et al., and Weinberg et al. (see below) are just a few examples of the many benefits of using nucleosome substrates for epigenetics studies.
EpiCypher leverages dNuc™ technology for a wide range of applications, including: SNAP-ChIP® Spike-in Controls (for antibody profiling and quantitative ChIP), EpiDyne® substrates (for characterizing chromatin remodeling enzyme complexes and inhibitors), and dCypher™ assays (for interrogation of epigenetic protein-histone PTM binding interactions). We also offer a suite of high-quality recombinant histone binding proteins, enzymes, peptides, antibodies, and custom assay development services to complement these platforms.
EpiCypher continuously pushes technology boundaries to deliver innovative products, solutions, and services to epigenetics and chromatin biology researchers. Most recently, EpiCypher has been at the leading edge of chromatin mapping technology improvements with the recent launch of the highly sensitive epigenomic mapping CUTANA™ assays for ChIC,
CUT&RUN, and CUT&Tag.
From our strong scientific expertise and rigor to our focus on customer success, EpiCypher is proud to be an epigenetics company For Scientists, By Scientists.